Consensus statements for management of Barrett's dysplasia and early-stage esophageal adenocarcinoma, based on a Delphi process

Cathy Bennett, Nimish Vakil, Jacques Bergman, Rebecca Harrison, Robert Odze, Michael Vieth, Scott Sanders, Laura Gay, Oliver Pech, Gaius Longcroft-Wheaton, Yvonne Romero, John Inadomi, Jan Tack, Douglas A. Corley, Hendrik Manner, Susi Green, David Al Dulaimi, Haythem Ali, Bill Allum, Mark AndersonHoward Curtis, Gary Falk, M. Brian Fennerty, Grant Fullarton, Kausilia Krishnadath, Stephen J. Meltzer, David Armstrong, Robert Ganz, Gianpaolo Cengia, James J. Going, John Goldblum, Charles Gordon, Heike Grabsch, Chris Haigh, Michio Hongo, David Johnston, Ricky Forbes–Young, Elaine Kay, Philip Kaye, Toni Lerut, Laurence B. Lovat, Lars Lundell, Philip Mairs, Tadakuza Shimoda, Stuart Spechler, Stephen Sontag, Peter Malfertheiner, Iain Murray, Manoj Nanji, David Poller, Krish Ragunath, Jaroslaw Regula, Renzo Cestari, Neil Shepherd, Rajvinder Singh, Hubert J. Stein, Nicholas J. Talley, Jean–Paul Galmiche, Tony C. K. Tham, Peter Watson, Lisa Yerian, Massimo Rugge, Thomas W. Rice, John Hart, Stuart Gittens, David Hewin, Juergen Hochberger, Peter Kahrilas, Sean Preston, Richard Sampliner, Prateek Sharma, Robert Stuart, Kenneth Wang, Irving Waxman, Chris Abley, Duncan Loft, Ian Penman, Nicholas J. Shaheen, Amitabh Chak, Gareth Davies, Lorna Dunn, Yngve Falck–ytter, John Decaestecker, Pradeep Bhandari, Christian Ell, S. Michael Griffin, Stephen Attwood, Hugh Barr, John Allen, Mark K. Ferguson, Paul Moayyedi, Janusz A. Z. Jankowski

Research output: Contribution to journalArticlepeer-review


Background & Aims  Esophageal adenocarcinoma (EA) is increasingly common among patients with Barrett's esophagus (BE). We aimed to provide consensus recommendations based on the medical literature that clinicians could use to manage patients with BE and low-grade dysplasia, high-grade dysplasia (HGD), or early-stage EA. 

Methods We performed an international, multidisciplinary, systematic, evidence-based review of different management strategies for patients with BE and dysplasia or early-stage EA. We used a Delphi process to develop consensus statements. The results of literature searches were screened using a unique, interactive, Web-based data-sifting platform; we used 11,904 papers to inform the choice of statements selected. An a priori threshold of 80% agreement was used to establish consensus for each statement. 

Results Eighty-one of the 91 statements achieved consensus despite generally low quality of evidence, including 8 clinical statements: (1) specimens from endoscopic resection are better than biopsies for staging lesions, (2) it is important to carefully map the size of the dysplastic areas, (3) patients that receive ablative or surgical therapy require endoscopic follow-up, (4) high-resolution endoscopy is necessary for accurate diagnosis, (5) endoscopic therapy for HGD is preferred to surveillance, (6) endoscopic therapy for HGD is preferred to surgery, (7) the combination of endoscopic resection and radiofrequency ablation is the most effective therapy, and (8) after endoscopic removal of lesions from patients with HGD, all areas of BE should be ablated. 

Conclusions We developed a data-sifting platform and used the Delphi process to create evidence-based consensus statements for the management of patients with BE and early-stage EA. This approach identified important clinical features of the diseases and areas for future studies.

Original languageEnglish
Pages (from-to)336-346
Issue number2
Publication statusPublished - 1 Aug 2012


Dive into the research topics of 'Consensus statements for management of Barrett's dysplasia and early-stage esophageal adenocarcinoma, based on a Delphi process'. Together they form a unique fingerprint.

Cite this